1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,021 | 0,023 | 10:24 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.01. | TRADING UPDATES: Genflow Biosciences lays out hopes for 2026 | 1 | Alliance News | ||
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 08.01. | Genflow: Gentherapie-Studie bei Hunden ohne unerwünschte Ereignisse | 1 | Investing.com Deutsch | ||
| 08.01. | Genflow reports no adverse events in dog aging gene therapy trial | 1 | Investing.com | ||
| 08.01. | Genflow Biosciences - Review of 2025 | - | RNS | ||
| 16.12.25 | Genflow Biosciences PLC: Genflow Completes Dosing Phase of Canine Gene Therapy Trial | 266 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 16.12.25 | Genflow Biosciences - Completion of Dosing Phase of Canine Gene Therapy | 1 | RNS | ||
| 11.12.25 | Genflow Biosciences to attend J.P. Morgan Healthcare Conference | 2 | Investing.com | ||
| 11.12.25 | Genflow Biosciences nimmt an J.P. Morgan Healthcare Conference teil | 4 | Investing.com Deutsch | ||
| 11.12.25 | Genflow Biosciences PLC: Genflow to Attend Healthcare Conference | 231 | ACCESS Newswire | Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference LONDON, UK / ACCESS Newswire / December 11, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), a... ► Artikel lesen | |
| 11.12.25 | Genflow Biosciences - Genflow to Attend Healthcare Conference | 2 | RNS | ||
| 31.10.25 | Genflow Biosciences PLC Announces Total Voting Rights | 247 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / October 31, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing... ► Artikel lesen | |
| 31.10.25 | Genflow Biosciences - Total Voting Rights | 2 | RNS | ||
| 24.10.25 | Genflow Biosciences PLC Announces Holding(s) in Company | 230 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / October 24, 2025 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason... ► Artikel lesen | |
| 22.10.25 | TRADING UPDATES: Genflow patent progress; Accsys new debt facilities | 2 | Alliance News | ||
| 22.10.25 | Genflow Biosciences announces second European patent application | 2 | Seeking Alpha | ||
| 22.10.25 | Genflow Biosciences PLC Announces Second European Patent Application | 269 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 22.10.25 | Genflow Biosciences - Second European Patent Application | 2 | RNS | ||
| 20.10.25 | Genflow Biosciences says European patent publication is "step forward" | 2 | Alliance News | ||
| 20.10.25 | Genflow Biosciences PLC Announces Recognition of Patentability of Claims | 216 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 20.10.25 | Genflow Biosciences - Recognition of Patentability of Claims | 2 | RNS |
1 2 3 4 Weiter >>
63 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 46,400 | -0,85 % | CRISPR Therapeutics-Aktie: Wird die Geduld belohnt? | Die Aktie von CRISPR Therapeutics sorgt seit Jahren für starke Volatilität in beide Richtungen und stellt selbst erfahrene Anleger vor Geduldsproben. Zwischen Hoffnungen auf medizinische Durchbrüche... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,047 | +1,29 % | PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases | MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced plans to pursue a strategic collaboration... ► Artikel lesen | |
| DENALI THERAPEUTICS | 16,235 | +0,28 % | Denali, Royalty Pharma Ink $275Mln Royalty Financing Agreement | WASHINGTON (dpa-AFX) - Denali Therapeutics Inc. (DNLI) and Royalty Pharma plc (RPRX) on Thursday announced a $275 million synthetic royalty funding agreement tied to future net sales of Tividenofusp... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,460 | +4,98 % | Voyager Therapeutics, Inc.: Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia | CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular... ► Artikel lesen | |
| BIOAGE LABS | 19,200 | +3,23 % | AKTIONÄR-Tipp BioAge Labs: Longevity-Aktie schießt über 27 Prozent hoch | Mit einem Kursplus von gut 27 Prozent gehörte die Aktie von BioAge Labs zum Start in die neue Handelswoche zu den absoluten Top-Performern an der Wall Street. Weitere Zwischenergebnisse zum großen Hoffnungsträger... ► Artikel lesen | |
| LINEAGE CELL THERAPEUTICS | 1,420 | -0,70 % | Lineage Cell Therapeutics highlights 2025 achievements in cell therapy | ||
| BIOPHYTIS | 0,062 | +0,82 % | BIOPHYTIS: Biophytis to Participate in the JP Morgan Healthcare Conference and the Biomed Forum | ||
| LONGEVERON | 0,565 | 0,00 % | Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy | The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammagingNo approved... ► Artikel lesen | |
| SERINA THERAPEUTICS | 2,300 | -3,36 % | Serina Therapeutics, Inc.: Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity | HUNTSVILLE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational... ► Artikel lesen | |
| IMMUNOME | 22,850 | 0,00 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| ERASCA | 9,560 | +14,90 % | Erasca, Inc.: Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones | Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,270 | -1,93 % | Summit Therapeutics: H.C. Wainwright bestätigt "Buy"-Rating und Kursziel von 40 US-Dollar | ||
| KYMERA THERAPEUTICS | 71,12 | -5,43 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs | KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 297,74 | -0,24 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy | BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,640 | 0,00 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report |
Das Unternehmen GENFLOW BIOSCIENCES PLC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,021 Euro und damit +10,81 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.